It’s time to rethink clinical trials in a post-pandemic world

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Becky Stephens is more than willing to go to great lengths for a miracle. With a diagnosis of stage 4 colon cancer and chemo treatments that weren’t working, she was desperate for hope—and found it in a clinical trial. 

So, the mother of three started making the often, four-hour round-trip trek from Santa Rosa to UCSF Medical Center every two weeks to participate. But the travel was tough. Aside from the cancer treatment leaving her exhausted, the long car trips were wearing on her. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Dana Dornsife
Founder and CEO, Lazarex Cancer Foundation
Table of Contents

YOU MAY BE INTERESTED IN

Acting Director Dr. Krzysztof Ptak’s words reverberated throughout the meeting room—and the heads of several of us—during the National Cancer Institute’s Office of Cancer Centers update on the final day of the 2024 Association of American Cancer Institutes/Cancer Center Administrators Forum Annual Meeting in Chicago.
“Bridge to Bahia” exhibit.Source: Sylvester Comprehensive Cancer CenterKaren Estrada, a survivor of acute myeloid leukemia, used visual art to communicate with her two boys while undergoing a bone marrow transplant at Sylvester Comprehensive Cancer Center. Because Estrada’s treatment required isolation, and her young children could not yet read and write, she sought out other creative vessels to foster closeness between them.
Dana Dornsife
Founder and CEO, Lazarex Cancer Foundation

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login